Reactome: A Curated Pathway Database

Query author contributions in Reactome

Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.

If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.

Name Email address

Pathways reviewed by Greulich, Heidi (1169426)

DB_ID Name
1236382 Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
5637815 Signaling by Ligand-Responsive EGFR Variants in Cancer
5637812 Signaling by EGFRvIII in Cancer
5637810 Constitutive Signaling by EGFRvIII
5638302 Signaling by Overexpressed Wild-Type EGFR in Cancer
5638303 Inhibition of Signaling by Overexpressed EGFR
1643713 Signaling by EGFR in Cancer

Details on Person Greulich, Heidi

_displayNameGreulich, Heidi
_timestamp2017-08-22 20:37:34
affiliation[Affiliation:1990846] Dana Farber Cancer Institute, Broad Institute
created[InstanceEdit:1169427] Orlic-Milacic, Marija, 2011-01-18
modified[InstanceEdit:1990847] Orlic-Milacic, Marija, 2011-11-14
[InstanceEdit:8932050] D'Eustachio, Peter, 2016-07-20
(author)[InstanceEdit:1990843] Greulich, H, 2011-11-15
[LiteratureReference:1169414] Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity
[LiteratureReference:1181018] Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants
[LiteratureReference:1182969] The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
[LiteratureReference:1228027] EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy
[LiteratureReference:1614274] Targeting mutant fibroblast growth factor receptors in cancer
[LiteratureReference:1637882] Drug-sensitive FGFR2 mutations in endometrial carcinoma
[LiteratureReference:1982030] Inhibitor-Sensitive FGFR1 Amplification in Human Non-Small Cell Lung Cancer
[LiteratureReference:2008165] Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain
[LiteratureReference:6802107] Somatic mutations affect key pathways in lung adenocarcinoma
[Change default viewing format]